IQVIA (IQV) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
28 Jul, 2026Executive summary
Q2 2026 revenue reached $4,368 million, up 8.7% year-over-year, with strong performance in both Commercial and R&D Solutions.
Adjusted EBITDA for Q2 was $994 million, up 9.2% year-over-year; Adjusted Diluted EPS was $3.15, up 12.1%.
Net income for Q2 2026 was $256 million ($1.53 per share); first half net income was $530 million ($3.14 per share).
Both Commercial and R&D Solutions segments delivered robust results, with strong bookings and expanding pipelines.
AI-enabled solutions are driving differentiation and higher win rates across all customer segments.
Financial highlights
First-half 2026 revenue was $8,519 million, up 8.6% year-over-year; Adjusted EBITDA was $1,926 million, up 7.4%.
Free cash flow for Q2 was $360 million, up 23% year-over-year; operating cash flow for Q2 was $558 million.
Share repurchases totaled $398 million in Q2, with $950 million repurchased in the first half; $2,819 million remains authorized.
Cash and cash equivalents at quarter-end were $1,909 million; net debt was $14,090 million.
Capital expenditures in Q2 were $198 million.
Outlook and guidance
Full-year 2026 revenue guidance raised to $17,275–$17,475 million (5.9%–7.1% growth), with a midpoint of 6.5%.
Adjusted EBITDA guidance raised to $4,000–$4,050 million (5.6%–6.9% growth); Adjusted Diluted EPS guidance raised to $12.80–$13.00 (7.4%–9.1% growth).
Q3 2026 revenue expected at $4,315–$4,390 million (5.2%–7.1% growth); adjusted EBITDA $1,000–$1,020 million; adjusted EPS $3.19–$3.29.
Guidance reflects higher organic growth, increased M&A contribution, and updated FX assumptions.
Approximately $36.4 billion in remaining performance obligations, with 30% expected to be recognized as revenue in the next 12 months.
Latest events from IQVIA
- Q2 2025 revenue rose 5.3% with robust segment growth, capital actions, and AI-driven innovation.IQV
Q2 20259 Jul 2026 - Q2 revenue rose 2.3% to $3.814B, with strong R&D growth, record backlog, and raised guidance.IQV
Q2 20248 Jul 2026 - Strong Q4 growth, robust AI-driven strategy, and stable margins support a positive outlook.IQV
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day8 Jul 2026 - Q1 2025 revenue up 2.5% to $3.83B; guidance raised; strong TAS and R&D performance.IQV
Q1 20258 Jul 2026 - Strong Q1 results, AI-driven growth, and rising demand signal industry recovery and expansion.IQV
Jefferies Global Healthcare Conference 20263 Jun 2026 - Strong Q1 growth, accelerating AI adoption, and robust capital deployment signal positive outlook.IQV
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue up 8.4%, net income $274M, and full-year EPS guidance raised.IQV
Q1 202612 May 2026 - AI adoption, biotech growth, and new acquisitions drive optimism and margin expansion.IQV
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - AI-driven efficiencies and the Cedar Gate acquisition strengthen patient analytics and growth.IQV
Leerink Global Healthcare Conference 20269 Mar 2026